An Open-label, Single-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2017
At a glance
- Drugs E 2027 (Primary) ; Diltiazem
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Co Ltd
- 06 Mar 2017 Status changed from active, no longer recruiting to completed.
- 23 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Jan 2017.
- 23 Dec 2016 Status changed from recruiting to active, no longer recruiting.